Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
24 participants
INTERVENTIONAL
2022-07-06
2026-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SV2A Density Cannabis Use Disorder
NCT05472818
The Neural Correlates of Cannabis Use
NCT03104257
Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals
NCT00158249
Cannabis Effects on Brain Morphology in Aging
NCT01874886
Repetitive Transcranial Magnetic Stimulation for Cannabis Use Disorder
NCT05859347
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cannabis using older adults
Subjects undergo a single PET scan using \[11C\]UCB-J
[11C]UCB-J PET
Single PET scan using the radioligand \[11C\]UCB-J
Healthy controls
Subjects undergo a single PET scan using \[11C\]UCB-J
[11C]UCB-J PET
Single PET scan using the radioligand \[11C\]UCB-J
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
[11C]UCB-J PET
Single PET scan using the radioligand \[11C\]UCB-J
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female, aged ≥50 years
* No history of significant medical or neurological disease
* BMI ≤ 50
* If woman of childbearing potential, must agree to use an acceptable method of birth control, as determined by the principal investigator, for the duration of the study and up to one month after completion of PET scans
Exclusion Criteria
* Have had exposure to ionizing radiation that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits;
* History of a bleeding disorder or are currently taking anticoagulants
* Subjects who have donated blood within 8 weeks of the present study
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
Yale University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Deepak C. D'Souza
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Deepak C D'Souza, MBBS, MD
Role: PRINCIPAL_INVESTIGATOR
Yale University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Conneticut Mental Health Center
New Haven, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2000032183
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.